Tumor necrosis factor-alpha and Interleukin-6 (TNF-α / IL-6)

Tumor necrosis factor-alpha (TNF-α) and Interleukin-6 (IL-6) are critical pro-inflammatory cytokines that orchestrate the body's immune and inflammatory responses (UniProt P01375, P05231). TNF-α is a potent pyrogen and mediator of acute inflammation, primarily produced by activated macrophages to trigger a cascade of other inflammatory mediators through the NF-κB pathway (PubMed: 21248125). IL-6 is a pleiotropic cytokine that promotes B-cell differentiation, T-cell activation, and the production of acute-phase proteins by the liver via the JAK/STAT signaling pathway (PubMed: 25124352). In many chronic inflammatory conditions, such as rheumatoid arthritis and inflammatory bowel disease, both cytokines are overproduced, leading to persistent tissue damage and systemic symptoms (StatPearls: TNF-alpha Inhibitors). Therapeutic intervention typically involves monoclonal antibodies or fusion proteins, such as adalimumab for TNF-α and tocilizumab for IL-6 signaling, designed to sequester these cytokines or block their receptors (FDA: Humira, Actemra). Dual inhibition of these pathways is an area of active research to address treatment resistance in complex autoimmune environments (PubMed: 28119442).

Other names

TNF-alphaIL-6Tumor necrosis factor ligand superfamily member 2B-cell stimulatory factor 2CTL differentiation factorHybridoma growth factorCachectinInterferon beta-2

Neutralization of circulating cytokines (TNF-α and IL-6) or their respective receptors to prevent downstream signaling through the NF-κB and JAK/STAT pathways, thereby reducing the production of inflammatory mediators and recruitment of immune cells.